Table 5. QOL evaluation (LC13).
Before therapy n=34 | After 4 weeks n=32 | After 12 weeks n=20 | |
---|---|---|---|
Symptom scales/items | |||
Dyspnoea | 12.5±17.1 | 14.0±17.7 | 11.1±16.4 |
Coughing | 32.3±15.8 | 24.7±21.0 | 22.2±16.4 |
Haemoptysis | 4.2±11.2 | 8.6±17.1 | 8.3±15.1 |
Sore mouth | 6.3±9.9 | 9.7±17.6 | 5.6±13.0 |
Dysphagia | 3.1±9.9 | 6.5±15.9 | 11.1±16.4 |
Peripheral neuropathy | 15.6±17.2 | 14.0±18.8 | 13.9±17.2 |
Alopecia | 3.1±13.0 | 7.5±18.7 | 16.7±17.4* |
Chest pain | 10.4±15.7 | 7.5±14.2 | 13.9±17.2 |
Arm or shoulder pain | 7.3±18.4 | 10.8±18.0 | 19.4±33.2 |
Pain in other regions | 26.9±27.8 | 18.3±20.8 | 16.7±17.4 |
QOL=quality of life; LC13=lung-cancer-specific module.
P<0.05 compared with before therapy.